Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 122
Filter
1.
Rev Esp Quimioter ; 35(5): 455-467, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35859521

ABSTRACT

OBJECTIVE: Risk factors (RFs) associated with infection progression in patients already colonised by carbapenem-resistant Gram-negative bacteria (CRGNB) have been addressed in few and disperse works. The aim of this study is to identify the relevant RFs associated to infection progression in patients with respiratory tract or rectal colonisation. METHODS: A systematic literature review was developed to identify RFs associated with infection progression in patients with CRGNB respiratory tract or rectal colonisation. Identified RFs were then evaluated and discussed by the expert panel to identify those that are relevant according to the evidence and expert's experience. RESULTS: A total of 8 articles were included for the CRGNB respiratory tract colonisation and 21 for CRGNB rectal colonisation, identifying 19 RFs associated with pneumonia development and 44 RFs associated with infection progression, respectively. After discussion, the experts agreed on 13 RFs to be associated with pneumonia development after respiratory tract CRGNB colonisation and 33 RFs to be associated with infection progression after rectal CRGNB colonisation. Respiratory tract and rectal colonisation, previous stay in the ICU and longer stay in the ICU were classified as relevant RF independently of the pathogen and site of colonisation. Previous exposure to antibiotic therapy or previous carbapenem use were also common relevant RF for patients with CRGNB respiratory tract and rectal colonisation. CONCLUSIONS: The results of this study may contribute to the early identification of CRGNB colonized patients at higher risk of infection development, favouring time-to-effective therapy and improving health outcomes.


Subject(s)
Gram-Negative Bacterial Infections , Pneumonia , Adult , Anti-Bacterial Agents/therapeutic use , Carbapenems/pharmacology , Carbapenems/therapeutic use , Consensus , Gram-Negative Bacteria , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , Humans , Pneumonia/drug therapy , Respiratory System , Risk Factors
2.
Rev Esp Quimioter ; 34(4): 298-307, 2021 Aug.
Article in Spanish | MEDLINE | ID: mdl-33913312

ABSTRACT

OBJECTIVE: The aim of the study is to identify risk factors associated to infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) and carbapenem-resistant Acinetobacter baumannii (CRAB) in adult patients through a systematic literature review, classify them according to their importance and provide recommendations by experts in the Spanish context. METHODS: We developed a systematic literature review to identify risk factors associated to CRPA or CRAB infections and they were evaluated and discussed by a multidisciplinary panel of experts. RESULTS: There were included 29 studies for P. aeruginosa and 23 for A. baumannii out of 593 identified through systematic literature review. We identified 38 risk factors for P. aeruginosa and 36 for A. baumannii. After risk factor evaluation by the panel of experts, results for CRPA were: 11 important, 10 slightly important and 15 unimportant risk factors; and for CRAB were: 9 important, 5 slightly important and 19 unimportant risk factors. For both pathogens, previous use of antibiotics and hospitalization were important risk factors. CONCLUSIONS: We could identify the main risk factors associated to CRPA and CRAB through literature review. There is a need for developing additional studies with higher levels of evidence to identify sooner and better infected patients through associated risk factors.


Subject(s)
Acinetobacter baumannii , Pseudomonas Infections , Adult , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Carbapenems/pharmacology , Humans , Microbial Sensitivity Tests , Pseudomonas Infections/drug therapy , Pseudomonas Infections/epidemiology , Pseudomonas aeruginosa , Risk Factors , Spain/epidemiology
3.
Clin Transl Oncol ; 21(6): 729-734, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30414063

ABSTRACT

INTRODUCTION: Cancer imposes a huge financial burden in all developed countries. This study estimates the burden of cancer in Spain in 2015. METHODS: The most recent available epidemiological data on prevalence, incidence and mortality, and the economic data on direct (hospital, drugs, and primary care) and indirect (productivity) costs was used from the social perspective. RESULTS: Prevalence, incidence, and mortality were, respectively, 1240, 478, and 218 per 100,000 inhabitants. Mortality was higher for men, while disability rates were higher for women. Direct costs accounted for 4818 million euros and indirect costs were 640 million euros in 2015. Direct costs were almost completely borne by the hospital (94%). Total burden of cancer in Spain was 5458 million euros in 2015. CONCLUSIONS: In Spain, the costs of cancer were mainly borne by the hospital and these costs might increase in the future due to the expected increase in longevity. Further research would be needed to investigate whether it is possible to redistribute the economic burden of cancer.


Subject(s)
Cost of Illness , Health Care Costs , Neoplasms/economics , Neoplasms/epidemiology , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Incidence , Infant , Male , Middle Aged , Neoplasms/therapy , Prevalence , Prognosis , Spain/epidemiology , Young Adult
4.
J Clin Endocrinol Metab ; 101(4): 1571-8, 2016 04.
Article in English | MEDLINE | ID: mdl-26771703

ABSTRACT

CONTEXT: Health-related quality of life (HRQoL) is impaired in primary hyperparathyroidism (PHPT) but instruments to specifically assess this are scarce. OBJECTIVE: Validate the new disease-specific Primary Hyperparathyroidism Quality of Life (PHPQoL) questionnaire in usual clinical practice. DESIGN: Observational, prospective, and multicenter. SETTING: Public hospital ambulatory care. PATIENTS: Patients with PHPT of both sexes, aged more than or equal to 18 years either initiated treatment for PHPT (group A) or had stable PHPT, not requiring therapy (group B). Patients in group A had at least one surgical criterion according to the 2009 Third International Workshop on Management of Asymptomatic PHPT. INTERVENTION: Sociodemographic, clinical, and HRQoL data (PHPQol, Short Form-36, Psychological Well-Being Index, and patients' self-perceived health status) were collected. Group A underwent 4 evaluations (baseline, 3 ± 1, 6 ± 1, and 12 ± 2 months after a therapeutic intervention) and group B 2, at baseline and 1 month later to assess test-retest reliability. RESULTS: A total of 182 patients were included (104 group A, 78 group B) with a mean age (SD) of 61.4 (12.1) years; 79.7% were women. Group A increased PHPQoL score (SD) (better HRQoL) (52 ± 23 at baseline; 62 ± 24 at 12 months; P < .001). At baseline, symptomatic patients had a lower PHPQoL score (worse) than asymptomatic ones (51 ± 21 vs 68 ± 21; P < .001). Correlations were seen between PHPQoL and Short Form-36, Psychological Well-Being Index, and self-perceived health status (P < .001). PHPQoL had good internal consistency (Cronbach's α = 0.80), test-retest reliability (group B, intraclass correlation coefficient > 0.80), and sensitivity to detect HQRoL changes over time. CONCLUSIONS: PHPQoL is a valid HRQoL measure to assess the impact of PHPT on health perception in clinical practice.


Subject(s)
Hyperparathyroidism, Primary/psychology , Psychometrics , Quality Indicators, Health Care/standards , Quality of Life , Female , Humans , Hyperparathyroidism, Primary/therapy , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Surveys and Questionnaires
5.
Qual Life Res ; 24(10): 2345-54, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25846413

ABSTRACT

PURPOSE: The COPD assessment test (CAT) is a questionnaire that assesses the impact of chronic obstructive pulmonary disease (COPD) on health status, but some patients have difficulties filling it up by themselves. We examined whether the mode of administration of the Spanish version of CAT (self vs. interviewer) influences its scores and/or psychometric properties. METHODS: Observational, prospective study in 49 Spanish centers that includes clinically stable COPD patients (n = 153) and patients hospitalized because of an exacerbation (ECOPD; n = 224). The CAT was self-administered (CAT-SA) or administered by an interviewer (CAT-IA) based on the investigator judgment of the patient's capacity. To assess convergent validity, the Saint George's Respiratory Disease Questionnaire (SGRQ) and the London Chest Activity of Daily Living (LCADL) instrument were also administered. Psychometric properties were compared across modes of administration. RESULTS: A total of 118 patients (31 %) completed the CAT-SA and 259 (69 %) CAT-IA. Multiple regression analysis showed that mode of administration did not affect CAT scores. The CAT showed excellent psychometric properties in both modes of administration. Internal consistency coefficients (Cronbach's alpha) were high (0.86 for CAT-SA and 0.85 for CAT-IA) as was test-retest reliability (intraclass correlation coefficients of 0.83 for CAT-SA and CAT-IA). Correlations with SGRQ and LCADL were moderate to strong both in CAT-SA and CAT-IA, indicating good convergent validity. Similar results were observed when testing longitudinal validity. CONCLUSIONS: The mode of administration does not influence CAT scores or its psychometric properties. Hence, both modes of administration can be used in clinical practice depending on the physician judgment of patient's capacity.


Subject(s)
Pulmonary Disease, Chronic Obstructive/diagnosis , Surveys and Questionnaires , Activities of Daily Living , Aged , Aged, 80 and over , Female , Follow-Up Studies , Health Status , Humans , Male , Middle Aged , Prospective Studies , Psychometrics/instrumentation , Quality of Life , Reproducibility of Results , Socioeconomic Factors , Spain
6.
Pituitary ; 17(2): 187-95, 2014 Apr.
Article in English | MEDLINE | ID: mdl-23564339

ABSTRACT

Cushing's syndrome (CS) has a considerable negative impact on patient health-related quality of life (HRQoL). Two disease-specific instruments (the CushingQoL and the Tuebingen CD-25 questionnaire) are now available to assess the impact of the disease and its treatment on HRQoL. The purpose of this review was to summarize the characteristics of the studies which have used these two instruments to date and summarize their findings regarding (a) the determinants of disease-specific HRQoL in patients with CS and (b) the impact of treatment for CS on disease-specific HRQoL. A total of 7 studies were identified, 5 with the CushingQoL and 2 with the Tuebingen CD-25. Most were observational studies, though the CushingQoL had been used in one randomized clinical trial. In terms of clinical factors, there was some evidence for an association between UFC levels and disease-specific HRQoL, though the presence and strength of the association varied between studies. There was also some evidence that a more recent diagnosis of CS could lead to poorer HRQoL, and that length of time with adrenal insufficiency may also affect HRQoL. There was no evidence for an impact on disease-specific HRQoL of etiology or of the clinical signs and symptoms associated with CS, such as bruising, rubor, and fat deposits. One factor which did have a significant negative effect on HRQoL was the presence of depression. No clear picture emerged as to the effect of demographic variables such as age and gender on HRQoL scores, though there was some evidence for poorer HRQoL in female patients. As regards treatment, the two interventions studied to date (transsphenoidal surgery and pasireotide) both showed significant gains in HRQoL, with moderate to large effect sizes. This type of review is useful in summarizing knowledge to date and suggesting future research directions.


Subject(s)
Cushing Syndrome/psychology , Cushing Syndrome/therapy , Quality of Life/psychology , Surveys and Questionnaires , Female , Humans , Male , Neurosurgical Procedures , Pituitary ACTH Hypersecretion/surgery , Psychometrics , Somatostatin/analogs & derivatives , Somatostatin/therapeutic use , Treatment Outcome
7.
Rev. clín. esp. (Ed. impr.) ; 213(8): 370-376, nov. 2013.
Article in Spanish | IBECS | ID: ibc-116062

ABSTRACT

Antecedentes y objetivo. Una de las complicaciones terapéuticas más importantes en los pacientes con diabetes mellitus (DM) es la hipoglucemia. Hemos estimado el número de hospitalizaciones por hipoglucemia grave en los pacientes con DM tipo 1 (DM1) y tipo 2 (DM2). Pacientes y métodos. El universo hospitalario se definió a partir del Catálogo Nacional de Hospitales (CNH) de 2007 (últimos datos disponibles), y se incluyeron 260 hospitales generales del Sistema Nacional de Salud. El número de hospitalizaciones por hipoglucemia grave fue extraído del Conjunto Mínimo Básico de Datos (CMBD) para 183 hospitales. Para los 77 restantes se estimó a partir de la información disponible. Resultados. En el año 2007 se produjeron un total de 26.701 (0,82%) hospitalizaciones con hipoglucemia. En los enfermos con DM2 se reportaron 8.242 (0,25%) ingresos como diagnóstico principal y 16.649 (0,51%) como secundario. En los pacientes con DM1 se reportaron 1.157 (0,04%) y 653 (0,02%) ingresos como diagnóstico principal y secundario, respectivamente. La incidencia global en DM2 fue de 1,82 episodios/10.000 habitantes/año, y osciló entre los 1,10 episodios/10.000 habitantes/año en Canarias y los 3,37 episodios en Castilla y León. Conclusiones. La hipoglucemia grave es una causa importante de hospitalización en los pacientes con DM en España, con una gran variabilidad entre CCAA (AU)


Background and objectives One of the most important therapeutic complications in patients with diabetes mellitus (DM) is hypoglycemia. This study has estimated the number of hospitalizations due to severe hypoglycemia in patients with type DM1 and DM2. Patients and methods. The study hospital population was defined using the National Catalogue of Hospitals (CNH) 2007 (last available data), and has included 260 general hospitals of the National Health System. The number of hospitalizations due to severe hypoglycemia was obtained from the Basic Minimum Data Set (BMDS) for the 183 hospitals. For the remaining 77 hospitals, this number was estimated based on the available information. Results. In 2007, there were 26,701 (0.82%) hospitalizations with hypoglycemia. In DM2 patients, 8,242 (0.25%) episodes were reported as primary diagnosis and 16,649 (0.51%) as secondary. In DM1 patients, 1,157 (0.04%) and 653 (0.02%) episodes were reported as primary and secondary diagnosis, respectively. Overall incidence in DM2 was 1.82 episodes/10,000 inhabitants-year, this ranging between 1.10 episodes/10,000 inhabitants-year in the Islas Canarias to 3.37 in Castilla y León. Conclusions. Severe hypoglycemia is an important reason for hospitalization of patients with DM in Spain, there being great variability according to the Autonomous Regions (AU)


Subject(s)
Humans , Male , Female , Hospitalization/economics , Hospitalization/statistics & numerical data , Length of Stay/economics , Hypoglycemia/complications , Hypoglycemia/economics , Hypoglycemia/epidemiology , Diabetes Mellitus/epidemiology , Diabetes Mellitus/prevention & control , National Health Systems , Hospitalization/legislation & jurisprudence , Hospitalization/trends , Retrospective Studies , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control
8.
Dig Dis Sci ; 58(12): 3400-6, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24026400

ABSTRACT

AIM: To evaluate the use of health care resources and the associated costs of complex perianal Crohn's disease (CD) from the National Health System perspective. METHODS: We conducted a multicenter, retrospective, observational study in which gastroenterologists from 11 hospitals in the Community of Madrid took part. Data was collected on the direct healthcare resources (pharmacological treatments, surgical procedures, laboratory/diagnostic tests, visits to specialists and emergency departments, and hospitalizations) consumed by 97 adult patients with complex perianal CD which was active at some point between January 1, 2005, and case history review. RESULTS: We recorded 527 treatments: 73.1% pharmacological (32.3% antibiotic, 20.5% immunomodulator, 20.3% biological) and 26.9% surgical. Mean annual global cost was €8,289/patient, 75.3% (€6,242) of which was accounted for by pharmacological treatments (€13.44 antibiotics; €1,136 immunomodulators; €5,093 biological agents), 12.4% (€1,027) by hospitalizations and surgery, 7.7% (€640) by medical visits, 4.2% (€350) by laboratory/diagnostic tests, and 0.4% (€30) by emergency department visits. CONCLUSIONS: Pharmacological therapies, and in particular biological agents, are the main cost driver in complex perianal CD; costs due to surgery and hospitalizations are much lower.


Subject(s)
Cost of Illness , Crohn Disease/economics , Health Care Costs/statistics & numerical data , Rectal Fistula/economics , Adult , Crohn Disease/complications , Crohn Disease/therapy , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Rectal Fistula/etiology , Rectal Fistula/therapy , Retrospective Studies
9.
Rev Clin Esp (Barc) ; 213(8): 370-6, 2013 Nov.
Article in English, Spanish | MEDLINE | ID: mdl-23683963

ABSTRACT

BACKGROUND AND OBJECTIVES: One of the most important therapeutic complications in patients with diabetes mellitus (DM) is hypoglycemia. This study has estimated the number of hospitalizations due to severe hypoglycemia in patients with type DM1 and DM2. PATIENTS AND METHODS: The study hospital population was defined using the National Catalogue of Hospitals (CNH) 2007 (last available data), and has included 260 general hospitals of the National Health System. The number of hospitalizations due to severe hypoglycemia was obtained from the Basic Minimum Data Set (BMDS) for the 183 hospitals. For the remaining 77 hospitals, this number was estimated based on the available information. RESULTS: In 2007, there were 26,701 (0.82%) hospitalizations with hypoglycemia. In DM2 patients, 8,242 (0.25%) episodes were reported as primary diagnosis and 16,649 (0.51%) as secondary. In DM1 patients, 1,157 (0.04%) and 653 (0.02%) episodes were reported as primary and secondary diagnosis, respectively. Overall incidence in DM2 was 1.82 episodes/10,000 inhabitants-year, this ranging between 1.10 episodes/10,000 inhabitants-year in the Islas Canarias to 3.37 in Castilla y León. CONCLUSIONS: Severe hypoglycemia is an important reason for hospitalization of patients with DM in Spain, there being great variability according to the Autonomous Regions.


Subject(s)
Diabetes Complications/epidemiology , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 2/complications , Hospitalization/statistics & numerical data , Hypoglycemia/epidemiology , Diabetes Complications/etiology , Humans , Hypoglycemia/etiology , Retrospective Studies , Severity of Illness Index , Spain
10.
Qual Life Res ; 22(10): 2941-50, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23539468

ABSTRACT

PURPOSE: To construct a model to predict preference-adjusted EuroQol 5D (EQ-5D) health utilities for CS using the disease-specific health-related quality of life measure (CushingQOL). METHODS: Data were obtained from the European Registry on CS (ERCUSYN). ERCUSYN is a web-based, multicenter, observational study that enrolled 508 CS patients from 36 centers in 23 European countries. Patients included in the study completed both the EQ-5D and the disease-specific CushingQOL questionnaire. Socio-demographic and clinical data were also collected. The UK tariff values were used to calculate EQ-5D utility scores. Various predictive models were tested, and the final model was selected based on four criteria: explanatory power (adjusted R-squared), consistency of estimated coefficients (sign and parameter estimation), normality of prediction errors (mean error, mean absolute error, root mean squared error), and parsimony. RESULTS: For the mapping analysis, data were available from a total of 129 patients. Mean (SD) age was 43.1 (13) years, and the sample was predominantly female (84.5 %). Patients had a mean (SD) CushingQOL score of 39.7 (17.1) and a mean (SD) 'tariff' value on the EQ-5D of 0.55 (0.3). The model which best met the criteria for selection included the intercept and 3 CushingQOL's questions and had an R(2) of 0.506 and a root mean square error of 0.216. CONCLUSIONS: It was possible to find a mapping function which successfully predicted the EQ-5D UK utilities from disease-specific CushingQOL scores. The function may be useful in calculating EQ-5D scores when EQ-5D data have not been gathered directly in a study.


Subject(s)
Cushing Syndrome/therapy , Health Status , Patient Preference , Quality of Life , Quality-Adjusted Life Years , Surveys and Questionnaires , Adult , Aged , Cushing Syndrome/psychology , Europe , Female , Health Services/statistics & numerical data , Humans , Male , Middle Aged , Models, Theoretical , Psychometrics , Registries , Regression Analysis
11.
Qual Life Res ; 20(10): 1727-36, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21479777

ABSTRACT

PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument's sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. RESULTS: Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording 'slight-moderate-severe' problems, with anchors of 'no problems' and 'unable to do' in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. CONCLUSIONS: A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects.


Subject(s)
Health Status Indicators , Psychometrics/instrumentation , Quality of Life , Activities of Daily Living , Adult , Female , Focus Groups , Humans , Interviews as Topic , Male , Middle Aged , Mobility Limitation , Pain Measurement , Reproducibility of Results , Self Care , Spain , United Kingdom
14.
Pediatr Pulmonol ; 44(1): 54-63, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19061230

ABSTRACT

OBJECTIVE: To develop and validate a questionnaire to assess asthma control in children (CAN). DESIGN: Two versions of the CAN (for carers and children) were developed. Both versions were validated in an observational, prospective, multicenter study performed in 38 hospital outpatient clinics throughout Spain. Four hundred fifteen patients and their carers agreed to participate. Of these, 414 patients under 14 years old with frequent episodic or persistent (moderate to severe) asthma completed the questionnaire on 3 occasions (baseline, week 2, and week 12). For patients aged 2-8 the questionnaire was only completed by the carers, but for patients aged 9-14 the questionnaire was completed by the carers and the children. Clinician ratings of asthma control were used as a gold standard to assess the sensitivity, specificity, PPV and NPV of the new measure. RESULTS: Evaluable responses were obtained from 215 carers for children aged 2-8 years and 199 children aged 9-14 years, and their parents. Using a questionnaire total score cut-off of 8 the patient version had a sensitivity of 76.3% and a specificity of 62.9%. For carer version these values were 73% and 69.7%, respectively. A cut point of 8 was selected to maximize the screening accuracy of the CAN questionnaire. Effect sizes in patients with clinician-rated improvements in asthma control were 0.33 and 0.57 for the carer and child versions, respectively. CONCLUSIONS: The screening accuracy and validity of the CAN questionnaire make it suitable for use in research and clinical practice. The sensitivity and specificity were close to 70%, which is acceptable for the study objective: obtain a tool to measure the level of asthma control.


Subject(s)
Asthma/diagnosis , Surveys and Questionnaires , Adolescent , Child , Child, Preschool , Female , Humans , Male , Mass Screening , Reproducibility of Results , Sensitivity and Specificity
15.
Rev Clin Esp ; 208(9): 437-43, 2008 Oct.
Article in Spanish | MEDLINE | ID: mdl-19000471

ABSTRACT

OBJECTIVES: To assess both management and evolution of diabetes mellitus type 2 (DM2) in Primary Care centers in Spain and the related factors, especially obesity. METHODOLOGY: Epidemiological, cross-sectional, multicenter, retrospective study. PATIENTS: Patients suffering from DM2, over 20 years of age, were consecutively enrolled from 30 Primary Care centers in 16 autonomous communities. Métodos. Data was collected on age, gender, educational level, DM2 duration, HbA1c, treatment and body measurement index (BMI). RESULTS: A total of 294 patients, 50% male, with a mean age (SD) of 67.5 years (10.2) and BMI 28.9 (4.5) kg/m(2) were included. Of them, 58.16% had HbA1c levels >6.5%, 38% being obese or severely obese. A total of 93.9% were under drug treatment for DM2. Significant differences in the mean value of HbA1c were shown between the over-weight and severely obese groups (Tukey-Kramer test). Differences were observed in the presence of macrovascular complications between patients with normal weight and patients with obesity (p=0.006). Patients with low educational level had 3.39 more probability of being obese or severely obese than patients with secondary school or university studies (p=0.0041; 95% CI 1.47-7.80), and patients with primary school 2.22 more probability (p= 0.038; 95% CI 1.04-4.73). A total of 47.8% reported high compliance. Obese and severely obese patients showed 2.2 more probability of having low or mild compliance than non-obese patients (p=0.002; 95% CI 1.31-3.74). CONCLUSIONS: Results obtained in this population suggest that obesity is related with more macro-vascular complications, worst metabolic control and worst compliance.


Subject(s)
Diabetes Complications/complications , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Obesity/complications , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
16.
Angiología ; 60(5): 333-345, sept.-oct. 2008. ilus, tab
Article in Es | IBECS | ID: ibc-68510

ABSTRACT

Introducción y objetivos. Las listas de espera gestionadas mediante el criterio first in-first served puede generarinequidades clínicas, sociales o éticas. Pretendemos establecer un sistema objetivo y equitativo de priorización de cirugíade varices. Sujetos y métodos. Basándonos en la metodología del ‘análisis de conjuntos’, se organizó un grupo focalcon pacientes estratificados por edad y afectación clínica, y otro con especialistas en Angiología y Cirugía Vasculary gestores del hospital promotor. Se determinaron las opiniones de cada colectivo y se elaboró un sistema preliminar conlos criterios seleccionados. Se ponderaron las categorías mediante entrevistas personales a 104 sujetos de la poblacióngeneral, seleccionados al azar. Las preferencias se estimaron mediante la técnica paramétrica de regresión multivariantedel logit ordenado. Se normalizaron los valores de los parámetros en una escala del 0 al 100. Resultados. El sistemade priorización final fue: gravedad de la patología (según la escala CEAP) leve (C2) 0 puntos, moderada (C3-C4) 18puntos, severa (C5-C6) 42 puntos; afectación de la calidad de vida (cuestionario CIVIQ-2) leve (CIVIQ-2 > 65) 0 puntos,moderada (CIVIQ-2 ≥ 30 y ≤ 65) 9 puntos, severa (CIVIQ-2 < 30) 19 puntos; sin circunstancias laborales agravantes0 puntos y con 17 puntos; tamaño de las varices pequeño (< 10 mm) 0 puntos y grande (≥ 10 mm) 9 puntos. Conclusión.El sistema de priorización de la lista de espera resultante contempla una visión integral de especialistas, gestores,pacientes y población general, e incluye criterios de gravedad de la patología, calidad de vida, presencia de complicaciones,circunstancias laborales agravantes y tamaño de las varices


Introduction and aims. Waiting lists that are managed by the ‘first in-first served’ criterion may give rise toclinical, social or ethical inequalities. Our aim is to establish an objective, fair system of prioritising varicose veinsurgery. Subjects and methods. Based on the 'conjoint analysis’methodology, one focus group patients were arranged instrata according to age and clinical disorder, and another was organised with specialists in Angiology and VascularSurgery and managers from the sponsoring hospital. The opinions of each collective were determined and a preliminarysystem was set up with the selected criteria. The categories were weighted with personal interviews held with 104randomly-chosen subjects from the general population. The preferences were estimated by means of the ordered logitmultivariate parametric regression technique. The values of the parameters were normalised on a scale from 0 to 100.Results. The final prioritisation system was: severity of the pathology (according to the CEAP scale): mild (C2) 0 points,moderate (C3-C4) 18 points, severe (C5-C6) 42 points; compromise of quality of life (CIVIQ-2 survey): mild (CIVIQ-2> 65) 0 points, moderate (CIVIQ-2 ≥ 30 and ≤ 65) 9 points, severe (CIVIQ-2 < 30) 19 points; with no aggravatingoccupational circumstances 0 points and 17 points with such circumstances; size of the varicose veins: small (< 10 mm)0 points and large (≥ 10 mm) 9 points. Conclusions. The resulting system for arranging a waiting list in order of prioritytakes into account an integrated vision by specialists, managers, patients and the general population, and includescriteria such as the severity of the pathology, quality of life, the presence of complications, aggravating occupationalcircumstances and the size of the varicose veins


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Varicose Veins/epidemiology , Varicose Veins/surgery , Waiting Lists , Waiting Lists , Patient Selection , Quality of Life , Multivariate Analysis , Logistic Models , Surveys and Questionnaires , Varicose Veins/classification , Varicose Veins/complications
17.
Rev. clín. esp. (Ed. impr.) ; 208(9): 437-443, oct. 2008. tab
Article in Es | IBECS | ID: ibc-71645

ABSTRACT

Objetivo. Estudiar el manejo y evolución de ladiabetes mellitus tipo 2 (DM2) en Atención Primaria(AP) en España y los factores implicados,especialmente la obesidad.Diseño. Estudio epidemiológico, transversal,multicéntrico, retrospectivo.Participantes. Se incluyeron pacientes con DM2mayores de 20 años seleccionadosconsecutivamente en 30 centros de AP, en16 comunidades autónomas (CCAA).Métodos. Se recogió información sobre edad, sexo,nivel educativo, duración de DM2, HbA1c,tratamiento e índice de masa corporal (IMC).Resultados. De un total de 294 pacientes, 50%hombres, con edad media (DE) 67,5 años (10,2) eIMC 28,9 (4,5) kg/m2, el 58,16% presentabanniveles de HbA1c >6,5%, el 38% era obeso oseveramente obeso. El 93,9% seguía tratamientofarmacológico para su diabetes. Se mostrarondiferencias significativas en el valor medio deHbA1c entre el grupo con sobrepeso y el grupocon obesidad severa (test de Tukey-Kramer).Se observaron diferencias en la presencia decomplicaciones macrovasculares entrepacientes con peso normal y pacientes obesos(p=0,006). Pacientes con menor grado dealfabetización mostraron 3,39 más probabilidad deser obesos o severamente obesos que pacientescon estudios secundarios o universitarios(p=0,0041; 95% intervalo de confianza [IC] 1,47-7,80), y los pacientes con estudios primarios 2,22veces más (p=0,038; 95% IC 1,04-4,73). Un47,8% refirieron un cumplimiento elevado. Losobesos y severamente obesos presentaron 2,2veces más probabilidad de presentar cumplimientobajo o moderado que los no obesos (p=0,002;95% IC 1,31-3,74 ).Conclusiones. Los resultados obtenidos en estapoblación sugieren que la variable obesidad serelaciona con más complicaciones macrovasculares,peor control metabólico y peor cumplimiento


Objectives. To assess both management andevolution of diabetes mellitus type 2 (DM2) inPrimary Care centers in Spain and the relatedfactors, especially obesity.Methodology. Epidemiological, cross-sectional,multicenter, retrospective study.Patients. Patients suffering from DM2, over 20years of age, were consecutively enrolled from 30Primary Care centers in 16 autonomouscommunities.Métodos. Data was collected on age, gender,educational level, DM2 duration, HbA1c, treatmentand body measurement index (BMI).Results. A total of 294 patients, 50% male, with amean age (SD) of 67.5 years (10.2) and BMI 28.9(4.5) kg/m2 were included. Of them, 58.16% hadHbA1c levels >6.5%, 38% being obese or severelyobese. A total of 93.9% were under drug treatmentfor DM2. Significant differences in the mean valueof HbA1c were shown between the over-weight andseverely obese groups (Tukey-Kramer test).Differences were observed in the presence ofmacrovascular complications between patients withnormal weight and patients with obesity (p=0.006).Patients with low educational level had 3.39 moreprobability of being obese or severely obese thanpatients with secondary school or university studies(p=0.0041; 95% CI 1.47-7.80), and patients withprimary school 2.22 more probability (p= 0.038;95% CI 1.04-4.73). A total of 47.8% reported highcompliance. Obese and severely obese patientsshowed 2.2 more probability of having low or mildcompliance than non-obese patients (p=0.002; 95%CI 1.31-3.74).Conclusions. Results obtained in this populationsuggest that obesity is related with more macrovascularcomplications, worst metabolic control andworst compliance


Subject(s)
Humans , Diabetes Mellitus, Type 2/complications , Obesity/complications , Retrospective Studies , Primary Health Care/trends , Diabetic Angiopathies/epidemiology
18.
J Clin Endocrinol Metab ; 93(10): 3853-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18647806

ABSTRACT

OBJECTIVE: The objective of the study was to assess whether weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment. DESIGN: This was a prospective, investigator-initiated, double blind, placebo-controlled, crossover study. Twenty acromegalic subjects received either PEG-V or placebo for two consecutive treatment periods of 16 wk, separated by a washout period of 4 wk. Efficacy was assessed as change between baseline and end of each treatment period. QoL was assessed by the Acromegaly Quality of Life Questionnaire (AcroQoL) and the Patient-Assessed Acromegaly Symptom Questionnaire (PASQ). RESULTS: The AcroQoL (P = 0.008) and AcroQoL physical (P = 0.002) improved significantly after PEG-V was added. The addition of PEG-V also significantly improved the PASQ (P = 0.038) and the single PASQ questions, perspiration (P = 0.024), soft tissue swelling (P = 0.036), and overall health status (P = 0.035). No significant change in Z-score of IGF-I (P = 0.34) was observed during addition of PEG-V. Transient liver enzyme elevations were observed in five subjects (25%). CONCLUSION: Improvement in quality of life was observed without significant change in IGF-I after the addition of 40 mg pegvisomant weekly to monthly SSA therapy in acromegalic patients who had normalized IGF-I on SSA monotherapy. These data question the current recommendations in how to assess disease activity in acromegaly. Moreover, the findings question the validity of the current approach of medical treatment in which pegvisomant is used only when SSA therapy has failed to normalize IGF-I.


Subject(s)
Acromegaly/drug therapy , Hormone Antagonists/administration & dosage , Human Growth Hormone/analogs & derivatives , Quality of Life , Somatostatin/analogs & derivatives , Acromegaly/psychology , Adult , Aged , Cross-Over Studies , Double-Blind Method , Drug Administration Schedule , Drug Combinations , Female , Hormone Antagonists/adverse effects , Human Growth Hormone/administration & dosage , Human Growth Hormone/adverse effects , Humans , Male , Middle Aged , Placebos , Somatostatin/administration & dosage , Somatostatin/adverse effects , Time Factors
19.
Actas Urol Esp ; 32(2): 230-9, 2008 Feb.
Article in Spanish | MEDLINE | ID: mdl-18409474

ABSTRACT

INTRODUCTION: Benign Prostatic Hyperplasia is a chronic disease that affects Health related quality of life (HRQL). In Spain there are no specific questionnaires to assess HRQL in patients suffering from BPH. The objective of this study was to validate the Spanish version of the Benign Prostatic Hyperplasia Impact Index (BII) questionnaire. MATERIAL AND METHODS: Study participants were men over 49 with confirmed BPH diagnosis and evaluated in three visits. Psychometric properties of the questionnaire were analyzed in terms of validity, reliability and sensitivity to change. RESULTS: A total of 1,719 men with mean (SD) age 68.36 were evaluated and classified according to the BPH severity. Both longitudinal and construct validity (r>0.6) of the BII questionnaire were moderate-high. Internal consistency (alpha=0.91), test-retest reliability (CCI=0.8) and sensitivity to change (effect size=0.6) showed good results. The HRQL improved significantly during the monitoring period (p<0.01). DISCUSSION: There were no available specific HRQL questionnaires for Spanish population with BPH until now. The Spanish version of the BII questionnaire fulfils with the psychometric properties that are necessary to evaluate HRQL in patients with BPH; furthermore, it has been confirm the considerable impact of this disease in the quality of life of this patients.


Subject(s)
Prostatic Hyperplasia , Quality of Life , Aged , Humans , Language , Male , Middle Aged , Prospective Studies
20.
Eur J Endocrinol ; 158(5): 623-30, 2008 May.
Article in English | MEDLINE | ID: mdl-18426820

ABSTRACT

UNLABELLED: Chronic exposure to hypercortisolism has significant impact on patient's health and health-related quality of life (HRQoL), as demonstrated with generic questionnaires. We have developed a disease-generated questionnaire to evaluate HRQoL in patients with Cushing's syndrome (CS; CushingQoL). OBJECTIVE: Validate the CushingQoL questionnaire in patients with CS in clinical practice conditions. DESIGN: Observational, international, cross-sectional study. METHODS: A total of 125 patients were recruited by 14 investigators from Spain, France, Germany, The Netherlands, and Italy over a 2-month period. Clinical and hormonal data were collected and correlated with results of the generic short form 36 (SF-36) questionnaire, a question on self-perceived general health status and the CushingQoL score. RESULTS: A total of 107 patients were pituitary-dependent and 18 adrenal-dependent CS; 104 (83%) were females, mean age 45 years (range 20-73 years); 39 (31%) were currently hypercortisolemic; and 47 (38%) adrenal insufficient. In clinical practice, CushingQoL was feasible (117; 94% of patients fully responded to the questionnaire in a mean time of 4 min), reliable (Crohnbach's alpha=0.87), and valid (factorial analysis demonstrated unidimensionality and Rasch analysis lead to a final version with 12 items). A significant (P<0.001) correlation was observed between CushingQoL score and patients self-perceived general health status and dimensions of SF-36 (Pearson's correlation coefficient > or =0.597). Patients with current hypercortisolism scored worse (lower) than those without (44+/-22 vs 56+/-21, P=0.004). Linear regression analysis identified female gender and hypercortisolism as significant predictors for worse QoL. CONCLUSION: CushingQoL is useful to evaluate HRQoL in patients with CS and correlates with clinical parameters.


Subject(s)
Cushing Syndrome/physiopathology , Cushing Syndrome/psychology , Health Status , Quality of Life , Surveys and Questionnaires/standards , Adult , Aged , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Models, Statistical , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...